Viewing Study NCT01973569

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:56 PM
Ignite Modification Date: 2026-01-03 @ 8:24 PM
Study NCT ID: NCT01973569
Status: COMPLETED
Last Update Posted: 2020-02-12
First Post: 2013-10-25
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
Sponsor: Daiichi Sankyo
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Rheumatoid Arthritis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Rheumatoid Arthritis View
None Denosumab View
None RANKL View
None RANK View
None AMG 162 View
None joint damage View
None Developmental Phase III View